GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,760
-630 (-3.84%)
Apr 28, 2026, 3:30 PM KST
12.81%
Market Cap 1.01T
Revenue (ttm) 5.84B
Net Income (ttm) -35.13B
Shares Out 64.24M
EPS (ttm) -604.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 769,417
Average Volume 682,466
Open 16,130
Previous Close 16,390
Day's Range 15,270 - 16,300
52-Week Range 11,290 - 24,900
Beta 0.60
RSI 58.26
Earnings Date n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

Financial Performance

In 2025, GI Innovation's revenue was 5.84 billion, an increase of 23943.39% compared to the previous year's 24.28 million. Losses were -35.13 billion, -40.23% less than in 2024.

Financial Statements

News

There is no news available yet.